Clinical trials: Chemotherapy-inducing Anemia
Chemotherapy Induced Anemia
A Study of AND017 in Cancer Related Anemic Patients Receiving Chemotherapy
The purpose of this study is to determine the safety and efficacy of AND017 after 6 weeks of treatment in patients with cancer-related anemia who are receiving chemotherapy.
- Trial name
- NCT06075030
- Testing
- AND017
- Volunteers
- 36 people
- Sponsor
- Kind Pharmaceuticals LLC
Leukemia, Myelodysplastic Syndromes
Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00002517
- Testing
- cytarabine, daunorubicin hydrochloride, dexamethasone
- Where
- 23 sites in Belgium, France and 1 more
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Antineoplastic Chemotherapy Induced Anemia
Epoetin Alfa (Hemax®) Phase IV Study in Chemotherapy Induced Anemia
The purpose of this study is to assess safety and efficacy of weekly epoetin alfa (Hemax® ) administered for 12 weeks in patients with non curable solid tumors or lymphoma with anemia (hemoglobin < 10g/dl) undergoing palliative…
- Trial name
- NCT01374373
- Testing
- Epoetin alfa
- Where
- 3 sites in Argentina
- Volunteers
- 30 people
- Sponsor
- Bio Sidus SA
Anemia, Cancer
A Study of PROCRIT (Epoetin Alfa) 80,000 Units (U) Once Every Four Weeks (Q4W) vs. 40,000 U Once Every Two Weeks (Q2W) in Cancer Patients Not Receiving Chemotherapy
The purpose of this study is to assess the safety and effectiveness of PROCRIT (Epoetin alfa) administered by injection subcutaneously (SC, under the skin), at a dose of 80,000 U once every four weeks or 40,000 U once every two…
- Conditions
- Anemia, Cancer, Epoetin Alfa
- Trial name
- NCT00306267
- Testing
- epoetin alfa
- Volunteers
- 61 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Anemia, Carcinoma, Non-Small-Cell Lung
To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer
The purpose of this study was to determine an effective and safe dose of sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia (CIA) in participants with metastatic non-small cell lung cancer (NSCLC) who are…
- Conditions
- Anemia, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small-Cell Lung, Bladder Cancer
- Trial name
- NCT01284348
- Testing
- Sotatercept 15 mg, Sotatercept 30 mg
- Volunteers
- 26 people
- Sponsor
- Merck Sharp & Dohme LLC
Anemia, Non-Myeloid Malignancies
Darbepoetin Alfa With or Without Intravenous (IV) Iron
To deterime the efficacy of 500 μg and 300 μg darbepoetin alfa administered subcutaneously (SC) on an every 3 weeks (Q3W) schedule, and the effect of intravenous (IV) iron supplementation in the treatment of anemia in patients…
- Trial name
- NCT00401544
- Testing
- darbepoetin alfa, IV iron dextran
- Volunteers
- 243 people
- Sponsor
- Amgen
Chemotherapy Induced Anemia, Cancer
Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy
The purpose of this study is to evaluate the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of multiple subcutaneously administered injections of peginesatide in anemic cancer participants receiving chemotherapy.
- Trial name
- NCT00272662
- Testing
- peginesatide
- Where
- 10 sites in Czechia, Poland and 1 more
- Volunteers
- 60 people
- Sponsor
- Affymax
Chronic Myeloproliferative Disorders, Leukemia
Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Thrombocytopenia
- Trial name
- NCT00003619
- Testing
- filgrastim, vitamin E, busulfan
- Where
- 2 sites in United States
- Sponsor
- Drexel University College of Medicine
Chemotherapy-induced Anemia, Non-myeloid Malignancies
Study of SSS06 for Chemotherapy-Induced Anemia in Non-Myeloid Malignancies
This study employs a multicenter, randomized, open-label, positive drug-controlled, multiple ascending dose clinical trial design to comprehensively evaluate the safety, tolerability, immunogenicity, and pharmacokinetic…
- Trial name
- NCT06854276
- Testing
- SSS06, rhEPO
- Volunteers
- 80 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Chemotherapy Induced Anemia
A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy
To evaluate the effectiveness and safety in randomized, double-blind, parallel-group study in anemic cancer patients undergoing chemotherapy
- Trial name
- NCT00144482
- Testing
- recombinant human erythropoietin
- Volunteers
- 122 people
- Sponsor
- Chugai Pharmaceutical
Anemia, Cancer
Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to Chemotherapy
This study will compare the efficacy (non-inferiority) of darbepoetin alfa (Aranesp®) extended dose schedule administration (EDS) versus darbepoetin alfa administered once per week (QW) in the treatment of anemia in subjects with…
- Trial name
- NCT00144131
- Testing
- Aranesp®
- Volunteers
- 750 people
- Sponsor
- Amgen
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia
Ex vivo expanded human myeloid progenitor cells (hMPCs; CLT-008) have the potential to accelerate neutrophil recovery and decrease the risk of febrile neutropenia and infection in patients receiving chemotherapy for acute…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Myelodysplasia
- Trial name
- NCT01297543
- Testing
- human myeloid progenitor cells, G-CSF
- Where
- 10 sites in United States
- Volunteers
- 45 people
- Sponsor
- Cellerant Therapeutics
Patients With Chemotherapy Induced Anemia (CIA)
Pharmacokinetic Study of Iron Isomaltoside 1000 Administered by 250 mg IV Bolus Injection or 500 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia
The purpose of this study is to assess Pharmakokinetic properties of iron isomaltoside 1000 (Monofer®) in doses of 250 mg and 500 mg in patients suffering from Chemotherapy Induced anemia.
- Trial name
- PK-CIA-06 (NCT01280240)
- Testing
- Monofer(R)
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Pharmacosmos A/S
Anemia
A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp®
The purpose of this trial is to prospectively assess the relationship between changes in hemoglobin (hgb) and changes in symptom burden associated with anemia in cancer patients receiving chemotherapy supported with Aranesp®.
- Trial name
- NCT00117117
- Testing
- Aranesp
- Volunteers
- 2,423 people
- Sponsor
- Amgen
Breast Neoplasms, Colorectal Neoplasms
Limiting Chemotherapy Side Effects by Using Moxa
This study investigates whether it is feasible to teach cancer patients undergoing chemotherapy to self-administer daily moxibustion to reduce chemotherapy side effects.
- Conditions
- Breast Neoplasms, Colorectal Neoplasms, Genital Neoplasms, Female, Toxicity Due to Chemotherapy
- Trial name
- NCT02781155
- Testing
- Moxibustion
- Where
- United Kingdom
- Volunteers
- 25 people
- Sponsor
- East and North Hertfordshire NHS Trust
Chemotherapy-induced Anaemia
Erythropoietin and Iron Supplementation for Patients With Chemotherapy-induced Anaemia
A multicentre, randomized, open-label, parallel-group, active controlled non-inferiority study
- Trial name
- NCT02731378
- Testing
- Erythropoietins (EPO), Aggressive iron dextran supplementation, Sustained iron dextran supplementation
- Where
- 6 sites in China
- Volunteers
- 603 people
- Sponsor
- Shanghai East Hospital
Cancer, Anemia
Efficacy and Safety of Heated Chinese Herb Medicine Patch Therapy on Chemotherapy-Induced Aplastic Anemia
The objective of this clinical trial is to establish a treatment for chemotherapy-induced pancytopenia symptoms using heated traditional Chinese medicine (TCM) plasters through a randomized, single-blind clinical trial.
- Trial name
- NCT07790692
- Testing
- The experimental group (heated TCM plaster group), Heat source without TCM plaster group, No heat source with TCM plaster group
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Hung-Rong Yen
Chemotherapy-induced Anemia, Non-Myeloid Malignancy
HEC53856 Tablets for Chemotherapy-induced Anemia in Non-myeloid Malignancies
A Phase II clinical trial to evaluate the efficacy and safety of different dosing regimens of HEC53856 tablets compared to rHuEPO injection in participants of the CIA trial.
- Trial name
- NCT07891377
- Testing
- HEC53856 tablet, rHuEPO injection
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Non-Myeloid Malignancies, Anemia
Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies
The purpose of this study is to characterize the pharmacokinetics/pharmacodynamics (PK/PD) of darbepoetin alfa administered at a subcutaneous (SC) dose of 0.45 mcg/kg three times weekly (TIW) in anemic patients with non-myeloid…
- Conditions
- Non-Myeloid Malignancies, Anemia, Cancer
- Trial name
- NCT00239239
- Testing
- Darbepoetin alfa
- Volunteers
- 44 people
- Sponsor
- Amgen
Anemia of Chronic Kidney Disease, Chemotherapy Effect
Desidustat in the Treatment of Chemotherapy Induced Anemia
This is a Phase 1, Open-label, Single Dose, Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Desidustat for treatment of anemia in patients receiving chemotherapy.
- Trial name
- NCT04667533
- Testing
- Desidustat
- Where
- India
- Volunteers
- 24 people
- Sponsor
- Zydus Lifesciences Limited